Polyethylene glycol–modified DOTAP:cholesterol/adenovirus hybrid vectors have improved transduction efficiency and reduced immunogenicity
Source abstract
Abstract
Despite the success of recombinant adenovirus serotype 5 (Ad5) and dioleoyltrimethylaminopropane:cholesterol (DOTAP:Chol) liposomes as viral and nonviral vectors in clinical trials, these vectors still suffer from drawbacks such as high immunogenicity and low transfection efficiency, respectively. To address these issues, some researchers have synthesized DOTAP:Chol/Ad5 hybrid vectors hoping to combine the unique features of the individual vectors. While this method shows promise, the limitations associated with Ad5 were not completely ameliorated. The objective of the present study was to use PEGylated liposomes to improve upon these previous studies, with the aim of maintaining high transduction efficiency and reducing the immune response. PEGylated DOTAP:Chol liposomes were synthesized at different molar ratios of polyethylene glycol (PEG) (0 to 0.04), and its effects on transduction efficiency and immunogenicity of Ad5 were studied. Coating of Ad5 with PEGylated liposomes was confirmed using transmission electron microscopy and dynamic light scattering, and these techniques indicated that the size of the complexes was ~ 140 nm. Transduction efficiency was enhanced nearly 100-fold in CAR-negative cells treated with PEGylated liposome/Ad5 complexes compared to unmodified Ad5. In addition, PEGylated liposome/Ad5 complexes significantly reduced the humoral and innate immune responses relative to native Ad5 as assessed by antiAd5 antibodies and IL-6 production by macrophage cells. Moreover, PEGylation decreased the cytotoxicity and hemolytic activity of the liposomes. In conclusion, the transduction efficiency, biocompatibility, and immunogenicity of DOTAP:Chol/Ad5 complexes were significantly improved by including an optimum amount of a PEG-lipid.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Virus-based gene therapy research · RNA Interference and Gene Delivery · Viral Infectious Diseases and Gene Expression in Insects
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (44)
Show source-provided references
1. Asaoka K, Tada M, Sawamura Y, Ikeda J, Abe H (2000) Dependence of efficient adenoviral gene delivery in malignant glioma cells on the expression levels of the Coxsackievirus and adenovirus receptor. J Neurosurg 92(6):1002–1008. https://doi.org/10.3171/jns.2000.92.6.100210.3171/jns.2000.92.6.1002 ↗
2. Basner-Tschakarjan E, Bijjiga E, Martino AT (2014) Pre-clinical assessment of immune responses to adeno-associated virus (AAV) vectors. Front Immunol 5:28–28. https://doi.org/10.3389/fimmu.2014.0002810.3389/fimmu.2014.00028 ↗
3. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW (1997) Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275(5304):1320–1323. https://doi.org/10.1126/science.275.5304.132010.1126/science.275.5304.1320 ↗
4. Beyerle A, Merkel O, Stoeger T, Kissel T (2010) PEGylation affects cytotoxicity and cell-compatibility of poly(ethylene imine) for lung application: structure-function relationships. Toxicol Appl Pharmacol 242(2):146–154. https://doi.org/10.1016/j.taap.2009.10.00110.1016/j.taap.2009.10.001 ↗
5. Bradley RR, Maxfield LF, Lynch DM, Iampietro MJ, Borducchi EN, Barouch DH (2012) Adenovirus serotype 5-specific neutralizing antibodies target multiple Hexon hypervariable regions. J Virol 86(2):1267–1272. https://doi.org/10.1128/jvi.06165-1110.1128/jvi.06165-11 ↗
6. Brunetti-Pierri N, Ng P (2011) Helper-dependent adenoviral vectors for liver-directed gene therapy. Hum Mol Genet 20(R1):R7–R13. https://doi.org/10.1093/hmg/ddr14310.1093/hmg/ddr143 ↗
7. Domanski DM, Klajnert B, Bryszewska M (2004) Influence of PAMAM dendrimers on human red blood cells. Bioelectrochemistry 63(1–2):189–191. https://doi.org/10.1016/j.bioelechem.2003.09.02310.1016/j.bioelechem.2003.09.023 ↗
8. Engler H, Machemer T, Philopena J, Wen SF, Quijano E, Ramachandra M, Tsai V, Ralston R (2004) Acute hepatotoxicity of oncolytic adenoviruses in mouse models is associated with expression of wild-type E1a and induction of TNF-alpha. Virology 328(1):52–61. https://doi.org/10.1016/j.virol.2004.06.04310.1016/j.virol.2004.06.043 ↗
9. Eto Y, Yoshioka Y, Ishida T, Yao X, Morishige T, Narimatsu S, Mizuguchi H, Mukai Y, Okada N, Kiwada H, Nakagawa S (2010) Optimized PEGylated adenovirus vector reduces the anti-vector humoral immune response against adenovirus and induces a therapeutic effect against metastatic lung cancer. Biol Pharm Bull 33(9):1540–1544. https://doi.org/10.1248/bpb.33.154010.1248/bpb.33.1540 ↗
10. Fausther-Bovendo H, Kobinger GP (2014) Pre-existing immunity against ad vectors: humoral, cellular, and innate response, what's important? Hum Vaccin Immunother 10(10):2875–2884. https://doi.org/10.4161/hv.2959410.4161/hv.29594 ↗
11. Fitzsimmons RE, Uludag H (2012) Specific effects of PEGylation on gene delivery efficacy of polyethylenimine: interplay between PEG substitution and N/P ratio. Acta Biomater 8(11):3941–3955. https://doi.org/10.1016/j.actbio.2012.07.01510.1016/j.actbio.2012.07.015 ↗
12. Fuxe J, Liu L, Malin S, Philipson L, Collins VP, Pettersson RF (2003) Expression of the coxsackie and adenovirus receptor in human astrocytic tumors and xenografts. Int J Cancer 103(6):723–729. https://doi.org/10.1002/ijc.1089110.1002/ijc.10891 ↗
13. Ginn SL, Amaya AK, Alexander IE, Edelstein M, Abedi MR (2018) Gene therapy clinical trials worldwide to 2017: an update. J Gene Med 20(5):e3015. https://doi.org/10.1002/jgm.301510.1002/jgm.3015 ↗
14. Gjetting T, Arildsen NS, Christensen CL, Poulsen TT, Roth JA, Handlos VN, Poulsen HS (2010) In vitro and in vivo effects of polyethylene glycol (PEG)-modified lipid in DOTAP/cholesterol-mediated gene transfection. Int J Nanomedicine 5:371–383. https://doi.org/10.2147/ijn.s1046210.2147/ijn.s10462 ↗
15. Hernandez Y, González-Pastor R, Belmar-Lopez C, Mendoza G, de la Fuente JM, Martin-Duque P (2019) Gold nanoparticle coatings as efficient adenovirus carriers to non-infectable stem cells. RSC Adv 9(3):1327–1334. https://doi.org/10.1039/C8RA09088B10.1039/C8RA09088B ↗
16. Immordino ML, Dosio F, Cattel L (2006) Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 1(3):297–31510.2217/17435889.1.3.297 ↗
17. Kim M, Zinn KR, Barnett BG, Sumerel LA, Krasnykh V, Curiel DT, Douglas JT (2002) The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells. Eur J Cancer 38(14):1917–1926. https://doi.org/10.1016/S0959-8049(02)00131-410.1016/S0959-8049(02)00131-4 ↗
18. Lechanteur A, Sanna V, Duchemin A, Evrard B, Mottet D, Piel G (2018) Cationic liposomes carrying siRNA: impact of lipid composition on physicochemical properties, cytotoxicity and endosomal escape. Nanomaterials (Basel) 8(5). https://doi.org/10.3390/nano805027010.3390/nano8050270 ↗
19. Lee CS, Bishop ES, Zhang R, Yu X, Farina EM, Yan S, Zhao C, Zheng Z, Shu Y, Wu X, Lei J, Li Y, Zhang W, Yang C, Wu K, Wu Y, Ho S, Athiviraham A, Lee MJ, Wolf JM, Reid RR, He TC (2017) Adenovirus-mediated gene delivery: potential applications for gene and cell-based therapies in the new era of personalized medicine. Genes Dis 4(2):43–63. https://doi.org/10.1016/j.gendis.2017.04.00110.1016/j.gendis.2017.04.001 ↗
20. Meunier-Durmort C, Picart R, Ragot T, Perricaudet M, Hainque B, Forest C (1997) Mechanism of adenovirus improvement of cationic liposome-mediated gene transfer. BBA - Biomembranes 1330(1):8–16. https://doi.org/10.1016/S0005-2736(97)00133-810.1016/S0005-2736(97)00133-8 ↗
21. Mori A, Chonn A, Choi LS, Israels A, Monck MA, Cullis PR (1998) Stabilization and regulated fusion of liposomes containing a cationic lipid using amphipathic polyethyleneglycol derivatives. J Liposome Res 8(2):195–211. https://doi.org/10.3109/0898210980903552610.3109/08982109809035526 ↗
22. Owens DE, Peppas NA (2006) Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 307(1):93–102. https://doi.org/10.1016/j.ijpharm.2005.10.01010.1016/j.ijpharm.2005.10.010 ↗
23. Park JW, Mok H, Park TG (2010) Physical adsorption of PEG grafted and blocked poly-L-lysine copolymers on adenovirus surface for enhanced gene transduction. J Control Release 142(2):238–244. https://doi.org/10.1016/j.jconrel.2009.11.00110.1016/j.jconrel.2009.11.001 ↗
24. Prill JM, Espenlaub S, Samen U, Engler T, Schmidt E, Vetrini F, Rosewell A, Grove N, Palmer D, Ng P, Kochanek S, Kreppel F (2011) Modifications of adenovirus hexon allow for either hepatocyte detargeting or targeting with potential evasion from Kupffer cells. Mol Ther 19(1):83–92. https://doi.org/10.1038/mt.2010.22910.1038/mt.2010.229 ↗
25. Roelvink PW, Lizonova A, Lee JGM, Li Y, Bergelson JM, Finberg RW, Brough DE, Kovesdi I, Wickham TJ (1998) The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J Virol 72(10):7909–791510.1128/JVI.72.10.7909-7915.1998 ↗
26. Schulte M, Sorkin M, Al-Benna S, Stupka J, Hirsch T, Daigeler A, Kesting MR, Steinau HU, Jacobsen F, Steinstraesser L (2013) Innate immune response after adenoviral gene delivery into skin is mediated by AIM2, NALP3, DAI and mda5. Springerplus 2(1):234. https://doi.org/10.1186/2193-1801-2-23410.1186/2193-1801-2-234 ↗
27. Sengupta S, Ulasov IV, Thaci B, Ahmed AU, Lesniak MS (2011) Enhanced transduction and replication of RGD-fiber modified adenovirus in primary T cells. PLoS One 6(3):e18091. https://doi.org/10.1371/journal.pone.001809110.1371/journal.pone.0018091 ↗
28. Simberg D, Weiss A, Barenholz Y (2005) Reversible mode of binding of serum proteins to DOTAP/cholesterol Lipoplexes: a possible explanation for intravenous lipofection efficiency. Hum Gene Ther 16(9):1087–1096. https://doi.org/10.1089/hum.2005.16.108710.1089/hum.2005.16.1087 ↗
29. Singarapu K, Pal I, Ramsey JD (2013) Polyethylene glycol-grafted polyethylenimine used to enhance adenovirus gene delivery. J Biomed Mater Res A 101(7):1857–1864. https://doi.org/10.1002/jbm.a.3448310.1002/jbm.a.34483 ↗
30. Singh R, Tian B, Kostarelos K (2008) Artificial envelopment of nonenveloped viruses: enhancing adenovirus tumor targeting in vivo. FASEB J 22(9):3389–3402. https://doi.org/10.1096/fj.08-10327510.1096/fj.08-103275 ↗
31. Sohaebuddin SK, Thevenot PT, Baker D, Eaton JW, Tang L (2010) Nanomaterial cytotoxicity is composition, size, and cell type dependent. Part Fibre Toxicol 7:22. https://doi.org/10.1186/1743-8977-7-2210.1186/1743-8977-7-22 ↗
32. Song LY, Ahkong QF, Rong Q, Wang Z, Ansell S, Hope MJ, Mui B (2002) Characterization of the inhibitory effect of PEG-lipid conjugates on the intracellular delivery of plasmid and antisense DNA mediated by cationic lipid liposomes. Biochim Biophys Acta 1558(1):1–13. https://doi.org/10.1016/s0005-2736(01)00399-610.1016/s0005-2736(01)00399-6 ↗
33. Steel JC, Cavanagh HM, Burton MA, Abu-Asab MS, Tsokos M, Morris JC, Kalle WH (2007) Increased tumor localization and reduced immune response to adenoviral vector formulated with the liposome DDAB/DOPE. Eur J Pharm Sci 30(5):398–405. https://doi.org/10.1016/j.ejps.2006.12.00410.1016/j.ejps.2006.12.004 ↗
34. Tomko RP, Xu R, Philipson L (1997) HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci U S A 94(7):3352–3356. https://doi.org/10.1073/pnas.94.7.335210.1073/pnas.94.7.3352 ↗
35. Toy R, Peiris PM, Ghaghada KB, Karathanasis E (2014) Shaping cancer nanomedicine: the effect of particle shape on the in vivo journey of nanoparticles. Nanomedicine (London) 9(1):121–134. https://doi.org/10.2217/nnm.13.19110.2217/nnm.13.191 ↗
36. Tran TTP, Eichholz K, Amelio P, Moyer C, Nemerow GR, Perreau M, Mennechet FJD, Kremer EJ (2018) Humoral immune response to adenovirus induce tolerogenic bystander dendritic cells that promote generation of regulatory T cells. PLoS Pathog 14(8):e1007127. https://doi.org/10.1371/journal.ppat.100712710.1371/journal.ppat.1007127 ↗
37. Vroman B, Ferreira I, Jerome C, Jerome R, Preat V (2007) PEGylated quaternized copolymer/DNA complexes for gene delivery. Int J Pharm 344(1–2):88–95. https://doi.org/10.1016/j.ijpharm.2007.06.04410.1016/j.ijpharm.2007.06.044 ↗
38. Vupputuri S, Karode S, Neely BJ, Ramsey JD (2013) Protein impurities from cell culture dramatically impact transduction efficiency of polymer/virus hybrid vectors. J Virol Methods 192(1):1–11. https://doi.org/10.1016/j.jviromet.2013.04.00710.1016/j.jviromet.2013.04.007 ↗
39. Wang W, Xiong W, Wan J, Sun X, Xu H, Yang X (2009) The decrease of PAMAM dendrimer-induced cytotoxicity by PEGylation via attenuation of oxidative stress. Nanotechnology 20(10):105103. https://doi.org/10.1088/0957-4484/20/10/10510310.1088/0957-4484/20/10/105103 ↗
40. Wheeler JJ, Palmer L, Ossanlou M, MacLachlan I, Graham RW, Zhang YP, Hope MJ, Scherrer P, Cullis PR (1999) Stabilized plasmid-lipid particles: construction and characterization. Gene Ther 6(2):271–281. https://doi.org/10.1038/sj.gt.330082110.1038/sj.gt.3300821 ↗
41. Yan X, Scherphof GL, Kamps JA (2005) Liposome opsonization. J Liposome Res 15(1–2):109–139. https://doi.org/10.1081/lpr-6497110.1081/lpr-64971 ↗
42. Yilmazer A, Al-Jamal WT, Van den Bossche J, Kostarelos K (2013) The effect of artificial lipid envelopment of adenovirus 5 (Ad5) on liver de-targeting and hepatotoxicity. Biomaterials 34(4):1354–1363. https://doi.org/10.1016/j.biomaterials.2012.10.05310.1016/j.biomaterials.2012.10.053 ↗
43. Yotnda P, Chen DH, Chiu W, Piedra PA, Davis A, Templeton NS, Brenner MK (2002) Bilamellar cationic liposomes protect adenovectors from preexisting humoral immune responses. Mol Ther 5(3):233–241. https://doi.org/10.1006/mthe.2002.054510.1006/mthe.2002.0545 ↗
44. Zhu Y, Li W, Li Q, Li Y, Li Y, Zhang X, Huang Q (2009) Effects of serum proteins on intracellular uptake and cytotoxicity of carbon nanoparticles. Carbon 47(5):1351–1358. https://doi.org/10.1016/j.carbon.2009.01.02610.1016/j.carbon.2009.01.026 ↗